home / stock / inmb / inmb quote
Last: | $ |
---|---|
Change Percent: | 3.27% |
Open: | $5.00 |
Close: | $5.05 |
High: | $5.30 |
Low: | $4.8001 |
Volume: | 22,030 |
Last Trade Date Time: | 02/12/2020 04:40:27 pm |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$ | $5.00 | $5.05 | $5.30 | $4.8001 | 22,030 | 02-12-2020 |
$ | $5.15 | $4.89 | $5.20 | $4.89 | 12,979 | 02-11-2020 |
$ | $4.96 | $5.075 | $5.25 | $4.85 | 35,299 | 02-10-2020 |
$ | $5.05 | $4.9851 | $5.09 | $4.876 | 17,276 | 02-07-2020 |
$ | $5.39 | $5.0272 | $5.40 | $4.90 | 17,544 | 02-06-2020 |
$ | $4.90 | $4.90 | $5.1031 | $4.90 | 7,740 | 02-05-2020 |
$ | $4.8441 | $4.7811 | $4.9123 | $4.70 | 15,667 | 02-04-2020 |
$ | $4.94 | $4.75 | $4.9531 | $4.75 | 12,019 | 02-03-2020 |
$ | $4.8614 | $4.93 | $5.00 | $4.85 | 4,282 | 01-31-2020 |
$ | $4.80 | $4.78 | $4.80 | $4.77 | 5,549 | 01-30-2020 |
$ | $5.2746 | $4.9198 | $5.2746 | $4.9198 | 8,917 | 01-29-2020 |
$ | $4.9785 | $5.1354 | $5.1354 | $4.9224 | 4,522 | 01-28-2020 |
$ | $5.03 | $4.82 | $5.0539 | $4.70 | 6,074 | 01-27-2020 |
$ | $5.24 | $4.995 | $5.24 | $4.98 | 19,577 | 01-24-2020 |
$ | $5.29 | $4.95 | $5.32 | $4.75 | 34,088 | 01-23-2020 |
$ | $5.6777 | $5.2502 | $5.6777 | $5.25 | 20,294 | 01-22-2020 |
$ | $5.58 | $5.60 | $5.6216 | $5.52 | 11,951 | 01-21-2020 |
$ | $5.68 | $5.66 | $5.7134 | $5.65 | 10,117 | 01-20-2020 |
$ | $5.68 | $5.66 | $5.7134 | $5.65 | 10,117 | 01-17-2020 |
$ | $5.6101 | $5.68 | $5.8382 | $5.57 | 13,358 | 01-16-2020 |
News, Short Squeeze, Breakout and More Instantly...
Enact Holdings Inc. (ACT) is expected to report $0.99 for Q1 2024 FormFactor Inc. (FORM) is expected to report $0.09 for Q1 2024 SAAB AB - Class B (SAABF) is expected to report for quarter end 2024-03-31 Lumos Pharma Inc. (LUMO) is expected to report $-1.21 for Q1 2024 Axis Capita...
Boca Raton, Florida, April 30, 2024 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, is pleased to share an up...
Boca Raton, Florida, April 29, 2024 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, continues to advance its Nat...